Intensity Therapeutics Net Income Over Time
| INTS Stock | 0.27 0.1 25.95% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Intensity Therapeutics Performance and Intensity Therapeutics Correlation. Intensity | Build AI portfolio with Intensity Stock |
Is there potential for Biotechnology market expansion? Will Intensity introduce new products? Factors like these will boost the valuation of Intensity Therapeutics. Market participants price Intensity higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Intensity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intensity Therapeutics is measured differently than its book value, which is the value of Intensity that is recorded on the company's balance sheet. Investors also form their own opinion of Intensity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intensity Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Intensity Therapeutics' market value can be influenced by many factors that don't directly affect Intensity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intensity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intensity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Intensity Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Intensity Therapeutics and related stocks such as Iterum Therapeutics PLC, Rallybio Corp, and iBio Common Stock Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ITRM | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (29.4 M) | (77.1 M) | (103.1 M) | (52 M) | (91.6 M) | (44.4 M) | (38.4 M) | (24.8 M) | (28.5 M) | (29.9 M) |
| RLYB | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (26.4 M) | (47 M) | (66.7 M) | (74.6 M) | (57.8 M) | (52 M) | (54.6 M) |
| IBIO | (1.7 M) | (5.7 M) | (6.2 M) | (3.7 M) | (6.6 M) | (9.8 M) | (14.5 M) | (16.1 M) | (17.6 M) | (16.4 M) | (23.2 M) | (50.4 M) | (29.3 M) | (24.9 M) | (18.4 M) | (16.5 M) | (17.4 M) |
| PLUR | (77.9 K) | (14.8 M) | (21.2 M) | (26.9 M) | (24.7 M) | (23.2 M) | (27.8 M) | (26.1 M) | (35.3 M) | (29.2 M) | (49.9 M) | (41.2 M) | (28.3 M) | (20.9 M) | (22.6 M) | (20.3 M) | (21.3 M) |
| BOLD | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (90.2 M) | (128.8 M) | (25.2 M) | (25.2 M) | (25.2 M) | (45.9 M) | (49.4 M) | (65.4 M) | (75.2 M) | (78.9 M) |
| PSTV | (2.1 M) | (32.5 M) | (32.3 M) | (26.2 M) | (37.4 M) | (18.7 M) | (22 M) | (22.7 M) | (12.6 M) | (10.9 M) | (8.2 M) | (13.4 M) | (20.3 M) | (13.3 M) | (13 M) | (11.7 M) | (12.3 M) |
| NXTC | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (22.8 M) | (33.7 M) | (33.2 M) | (69.4 M) | (69.4 M) | (62.7 M) | (55.7 M) | (50.1 M) | (52.6 M) |
| ANTX | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (13.6 M) | (21.5 M) | (41.5 M) | (64.7 M) | (51.3 M) | (46.2 M) | (48.5 M) |
| QTTB | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (30 M) | (55.6 M) | (103.9 M) | (128.7 M) | (95.8 M) | (42.8 M) | (53.7 M) | (47.7 M) | (43 M) | (45.1 M) |
Intensity Therapeutics and related stocks such as Iterum Therapeutics PLC, Rallybio Corp, and iBio Common Stock Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Intensity Therapeutics financial statement analysis. It represents the amount of money remaining after all of Intensity Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Intensity Therapeutics Common | INTS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1 Enterprise Drive, |
| Exchange | NASDAQ Exchange |
null 0.274
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics' price analysis, check to measure Intensity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics is operating at the current time. Most of Intensity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics' price. Additionally, you may evaluate how the addition of Intensity Therapeutics to your portfolios can decrease your overall portfolio volatility.